ClinicalTrialsFinder

Triple-Negative Breast Cancer Clinical Trials in Buenos Aires, Buenos Aires F.D.

1 recruitingBuenos Aires, Buenos Aires F.D., Argentina

Showing 1–1 of 1 trials

Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374